Novo’s $1.4 Billion Orbis Deal Does Not Say What It Paid at Signing
The headline has no denominator. Upfront and milestones are stated as one number, which makes the commitment impossible to assess.
Orbis Medicines
The headline has no denominator. Upfront and milestones are stated as one number, which makes the commitment impossible to assess.